Latest Antisense news

Latest Antisense
News & Updates.

6 months ago

Shareholder Newsletter

7 months ago

Chief Executive Officer and Managing Director Appointment

8 months ago

ATL1102 Phase IIb DMD trial – Bulgarian approval received – UK and Australian approval process advancing

8 months ago

Quarterly Activities Report & Appendix 4C

9 months ago

Dosing Commenced in the ATL1102 toxicology study

10 months ago

Receipt of R&D Tax Incentive Payment

10 months ago

First approval received for ATL1102 Phase IIb DMD clinical trial

10 months ago

Dosing commenced in Limb Girdle Muscular Dystrophy R2 animal study

10 months ago

Positive Outcomes in DMD combination animal study

1 year ago

Annual General Meeting Results

1 year ago

Antisense Therapeutics CEO announces retirement

1 year ago

ATL1102 toxicology study to support clinical program in the US

1 year ago

Online Meeting Guide for Annual General Meeting 17 November 2022

1 year ago

Notice of Annual General Meeting

1 year ago

Company Appointment – Chief Commercial Officer